The US Food and Drug Administration’s approval of Agios Pharmaceuticals, Inc.’s Pyrukynd (mitapivat) capped a strong week for rare diseases at the agency.
Three of the six novel agents approved in 2022 so far by the Center for Drug Evaluation and Research have...







